-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-IN-22
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2710278-53-6.gif)
| Category | SARS-CoV |
| CAS | 2710278-53-6 |
| Description | SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals. |
Product Information
| Synonyms | SARS-CoV-2-IN-22|HY-146157 |
| Molecular Weight | 456.56 |
| Molecular Formula | C27H24N2O3S |
| Canonical SMILES | C=CCC1=CC(=C(C(=C1)C2=CC(=C(C=C2)O)CC=C)O)CSC3=NN=C(O3)C4=CC=CC=C4 |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 629 |
| Exact Mass | 456.15076381 |
| In Vitro | SARS-CoV-2-IN-22 (Compound 9a) effectively blocks the binding of SARS-CoV-2 to the host ACE2 receptor through dual recognition of SARS-CoV-2 spike receptor-binding domain (RBD) and human ACE2. SARS-CoV-2-IN-2 displays no cytotoxicity to normal cells (LO2). |
| Target | IC50: 16.96 µM (SARS-CoV-2) |
| XLogP3-AA | 6.8 |
